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Global and regional risk of disabling sequelae from bacterial 
meningitis: a systematic review and meta-analysis
Karen Edmond, Andrew Clark, Viola S Korczak, Colin Sanderson, Ulla K Griﬃ  ths, Igor Rudan
Few data sources are available to assess the global and regional risk of sequelae from bacterial meningitis. We aimed 
to estimate the risks of major and minor sequelae caused by bacterial meningitis, estimate the distribution of the 
diﬀ erent types of sequelae, and compare risk by region and income. We systematically reviewed published papers 
from 1980 to 2008. Standard global burden of disease categories (cognitive deﬁ cit, bilateral hearing loss, motor deﬁ cit, 
seizures, visual impairment, hydrocephalus) were labelled as major sequelae. Less severe, minor sequelae (behavioural 
problems, learning diﬃ  culties, unilateral hearing loss, hypotonia, diplopia), and multiple impairments were also 
included. 132 papers were selected for inclusion. The median (IQR) risk of at least one major or minor sequela after 
hospital discharge was 19·9% (12·3–35·3%). The risk of at least one major sequela was 12·8% (7·2–21·1%) and of at 
least one minor sequela was 8·6% (4·4–15·3%). The median (IQR) risk of at least one major sequela was 24·7% 
(16·2–35·3%) in pneumococcal meningitis; 9·5% (7·1–15·3%) in Haemophilus inﬂ uenzae type b (Hib), and 7·2% 
(4·3–11·2%) in meningococcal meningitis. The most common major sequela was hearing loss (33·9%), and 19·7% 
had multiple impairments. In the random-eﬀ ects meta-analysis, all-cause risk of a major sequela was twice as high in 
the African (pooled risk estimate 25·1% [95% CI 18·9–32·0%]) and southeast Asian regions (21·6% [95% CI 
13·1–31·5%]) as in the European region (9·4% [95% CI 7·0–12·3%]; overall I²=89·5%, p<0·0001). Risks of long-term 
disabling sequelae were highest in low-income countries, where the burden of bacterial meningitis is greatest. Most 
reported sequelae could have been averted by vaccination with Hib, pneumococcal, and meningococcal vaccines. 
Introduction
Published reviews of bacterial meningitis incidence and 
case fatality hide the true impact of bacterial meningitis 
on families and communities. Survivors of bacterial 
meningitis are at risk from long-term disabling sequelae 
and impaired quality of life,1 but disabled children and 
adults are hidden from view in many societies, subjected 
to stigma and neglect, and undercounted in national and 
international statistics.2 
Few data sources are available for paediatricians and 
public-health researchers to assess the long-term risk of 
disability associated with bacterial meningitis across 
countries and regions. There is also little information 
about the severity and distribution of the diﬀ erent types 
of sequelae. Additionally, the ﬁ nancial burden that 
families incur in caring for disabled individuals is 
commonly not calculated or is underestimated.3 Data are 
especially poor from low-income countries, where the 
risks of infection are highest and care is least accessible. 
Indeed, previous systematic reviews of the long-term 
outcomes from bacterial meningitis focused on studies 
from high-income countries.1,4 
The risk of sequelae from bacterial meningitis has 
probably changed since these systematic reviews were 
published because of improvements in antibiotics and 
supportive therapies to treat acute episodes of bacterial 
meningitis. Clinicians are now using highly sensitive tests 
to diagnose long-term disabling sequelae that would have 
previously remained undetected. Additionally, coverage of 
conjugate vaccines against the main causes of bacterial 
meningitis (Haemophilus inﬂ uenzae type b [Hib], 
Streptococcus pneumoniae [pneumococcus], and Neisseria 
meningitidis [meningococcus]) has increased.5 These factors 
might inﬂ uence risks of sequelae in diﬀ erent ways. 
Our aims were to estimate the risks of major and minor 
sequelae caused by bacterial meningitis, to estimate the 
distribution of the diﬀ erent types of sequelae, and to 
compare sequelae risk by region and gross national 
income (GNI).
Methods
Search strategy and selection criteria
The initial search of Medline and WHOLIS databases 
aimed to be as inclusive as possible, and used the search 
terms “meningitis, bacterial”[Mesh] AND 
“complications”[Subheading], limited to human studies 
published between Jan 1, 1980 and Mar 1, 2008 (ﬁ gure 1). 
We restricted our search up to March, 2008, to maintain 
consistency and comparability with other WHO Global 
Burden of Disease (GBD) and Child Health Epidemiology 
Reference Group publications aimed at producing estimates 
for the year 2008.6,7,8 We also contacted experts and searched 
reference lists of articles to obtain unpublished data. There 
were no language restrictions. 
We deﬁ ned bacterial meningitis according to the 2001 
GBD Disease Control Priorities Project (DCPP)9 as an 
acute bacterial disease with sudden onset of fever, 
intense headache, nausea, vomiting, or neck stiﬀ ness. 
The clinical diagnosis of meningitis had to be 
accompanied by laboratory evidence (in cerebrospinal 
ﬂ uid or blood) of a recognised bacterial pathogen (eg, 
Hib, pneumococcus, or meningococcus).9 We did not 
include tuberculous or viral diseases, because their 
natural history and sequelae risks are substantially 
diﬀ erent from those of bacterial pathogens such as Hib, 
pneumococcus, and meningococcus. 
A sequela was deﬁ ned according to the GBD DCPP as 
a health state resulting from meningitis for which 
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epidemiological estimates (incidence, prevalence, average 
duration) and a single average disability weight could be 
calculated.9 It included all current and future functional 
health states (until remission to full health or death) in 
the natural history of the disease that impaired quality of 
life or activities of daily living. 
The GBD DCPP has deﬁ ned a group of severe sequelae 
(table 1), which we retained for use in this study and 
labelled as major sequelae.9 We also developed a set of 
other commonly reported minor sequelae that were less 
severe but still impaired quality of life and activities of 
daily living (table 1). A separate category was also created 
to identify individuals with more than one sequela 
(multiple impairments), because bacterial meningitis 
results in parenchymal brain damage and deﬁ cits in 
many diﬀ erent domains. Multiple impairments were 
also stratiﬁ ed into major and minor categories. All 
sequelae were allocated an International Classiﬁ cation of 
Diseases, 10th edition (ICD-10) code.10 
Papers were excluded if they did not report the following: 
numbers of laboratory-conﬁ rmed pathogens, a deﬁ ned 
denominator of meningitis patients, sequelae of 
meningitis, associated health/functional states, original 
data; or if the papers only included neonates (ie, newborns 
up to 1 month of age). Neonates were excluded because 
the causal organisms, potential interventions (including 
maternal health care), and policy implications are diﬀ erent 
to those for older infants, children, and adults. 
GBD, major sequelae Non-GBD, minor sequelae
Case deﬁ nition ICD10 codes Case deﬁ nition ICD10 codes
Cognitive Mental retardation with IQ <70 F70–F79, F06.7 Learning diﬃ  culties or deﬁ cits in IQ with IQ >70 or speech/
language impairment 
F06.7, F80.0, F81.0, 
F81.2, F81.8, F81.9
Seizures Seizures of any type G40 .. ..
Hearing Bilateral sensorineural hearing loss with audiometric 
hearing threshold level (averaged over 0·5 kHz, 1 kHz, 
2 kHz, 4 kHz in the better ear) of >26 dB hearing level  
H90.3, H90.5 Unilateral sensorineural hearing loss with audiometric hearing 
threshold level (averaged over 0·5 kHz, 1 kHz, 2 kHz, 4 kHz) of 
>26 dB hearing level
H90.4, H90.7
Motor Impairment, spasticity or paresis of one or more limbs G80, G81.1, G82.1, 
G83.0–G83.3 G24.9, 
G25.3, G25.5, G25.9
Isolated hypotonia, motor delay, ataxia, gait or coordination 
diﬃ  culties 
F82, R26–R27
Vision Presenting visual acuity in the best eye of less than 6/12 or 
corresponding visual ﬁ eld loss 
H47, H53.4 Unilateral visual disturbance, diplopia, nystagmus, or cranial 
nerve dysfunction 
H49-51, H53.0, H53.2, 
H53.4, H54.4–H54.7
Behaviour .. .. Any behavioural disorder attributed to the meningitis episode F90–98
Clinical Distinct pathological entity with any impairment to 
activities of daily living (ie, hydrocephalus)
G91.1, T85.0 Distinct pathological entity with no impairment to activities of 
daily living (ie, mild cerebral dilatation) 
G91.2
Multiple 
impairments
At least two of above domains .. At least two of above domains, or developmental delay not 
otherwise speciﬁ ed
..
GBD=Global Burden of Disease Project.9 ICD10=International Classiﬁ cation of Diseases, 10th edition.10 IQ=intelligence quotient.
Table 1: Case deﬁ nitions and domains
Figure 1: Search results 
Numbers in ﬁ nal row do not sum to the total number of papers included (n=132) because some papers are included in more than one category.
87 studies with all-cause meningitis
      sequelae (59 post discharge)
33 studies with Hib meningitis
      sequelae (27 post discharge)
132 papers included in review
356 studies not included
           15 only included infants aged <28 days
           15 had no laboratory-conﬁrmed pathogens
        137 did not deﬁne denominator of meningitis patients
        128 reported no meningitis sequelae
           17 had no associated health/functional state
          44 did not use original data
488 abstracts selected
2771 titles identiﬁed from Medline/WHOLIS search
27 studies with pneumococcal 
      meningitis sequelae (20 post 
      discharge)
35 studies with meningococcal
      meningitis sequelae (27 post 
      discharge)
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Data extraction
Two reviewers (KE and VSK) examined titles, abstracts, 
and papers independently with identical case deﬁ nitions 
(table 1), data abstraction forms, and selection criteria. 
Reviewers also classiﬁ ed the studies according to WHO 
region (African, South East Asian, Western Paciﬁ c, 
Eastern Mediterranean, European, and American 
regions) and WHO mortality strata.11 Disagreements 
were resolved by consensus between the two reviewers 
and the lead authors (KE, VSK, AC, CS).
An initial review of bacterial meningitis studies 
indicated that sequelae were reported at either the time 
of discharge from hospital (“at discharge”) or during the 
follow-up period after discharge home from hospital 
(“post discharge”). We decided to describe both sets of 
data, but to focus the main analysis on the post-discharge 
sequelae. This is because symptoms (eg, malaise) from 
acute meningitis infection persist until hospital 
discharge, and patients’ responses to hospital neurological 
examinations are often suboptimum (especially cognitive 
and hearing examinations). More representative 
examinations occur after patients have had time to 
recover from the acute illness and return home to a 
familiar environment (post discharge).12,13 
Analyses
We ﬁ rst described the results using medians (IQR) of the 
proportion of individuals with any (at least one) sequelae 
resulting from bacterial meningitis. Major, minor, and 
total (major or minor) sequelae risks were calculated 
separately for all-cause and pathogen-speciﬁ c (Hib, 
pneumococcus, and meningococcus) meningitis. 
Two types of adjustment were required to estimate the 
median (IQR) risk by domain (ie, risk of the diﬀ erent 
types of sequelae). First, many studies reported person 
counts for each domain independently (eg, percentage 
with hearing loss, percentage with motor deﬁ cit) and did 
not report the number of people with multiple 
impairments (eg, percentage with both hearing loss and 
motor deﬁ cit). We decided to retain these studies to avoid 
unnecessary data loss, but to convert the counts into 
mutually exclusive categories (eg, percentages with only 
hearing loss, with only motor deﬁ cit, with both hearing 
loss and motor deﬁ cit). To do this, we selected all studies 
that reported both independent and mutually exclusive 
counts and identiﬁ ed the mean ratio between these two 
indicators. These ratios were then applied to all studies 
that reported only independent counts so that mutually 
exclusive counts could be generated for all studies. 
Second, many studies did not report on all domains. 
In some cases this was due to the design of the study (eg, 
some studies were only designed to assess audiological 
sequelae and individuals were not examined for motor 
deﬁ cit or other abnormalities). In other cases, no 
sequelae were reported for a given domain and it was 
not clear whether the study had been designed to 
examine this domain. Domain-speciﬁ c risks were 
calculated based only on the studies that examined a 
given domain, but all domain-speciﬁ c risks were adjusted 
to ensure they summed to the estimated overall risk of 
experiencing at least one sequela. 
We used random-eﬀ ects meta-analysis to investigate 
the impact of the following covariates on risk of sequelae: 
WHO region, WHO mortality strata, GNI band, decade 
of data collection, age-group (<5 years, ≥5 years), study 
design (prospective, retrospective), duration of follow-up 
after hospital discharge, and percentage of cases with 
laboratory conﬁ rmation of the pathogen. The only 
outcome considered in these analyses was the proportion 
of patients with bacterial meningitis who had at least 
one major sequela. Each covariate was categorical with 
clearly deﬁ ned subgroups. Thus, for each covariate we 
ﬁ rst did a random-eﬀ ects meta-analysis of all available 
studies within the subgroups to impute estimates (eg, for 
age-group, we imputed estimates for patients aged 
<5 years and ≥5 years separately). We then did a bivariate 
metaregression analysis in which we examined each 
covariate ﬁ tted individually as a single factor in isolation 
and compared estimates with the most prevalent 
subgroup (eg, for age-group, we compared estimates for 
patients aged 5 years with those aged ≥5 years). Finally, 
we did a multivariate analysis in which we included all 
important covariates (GNI band, decade of data 
collection, age-group, study design, duration of follow-
up after hospital discharge, and percentage of cases with 
laboratory conﬁ rmation of the pathogen) in a multivariate 
metaregression model and obtained ﬁ nal estimates of 
the proportion of people with at least one major sequela 
adjusting for the eﬀ ect of these covariates. WHO region, 
WHO mortality band, and GNI were highly correlated 
and therefore only GNI was included in this ﬁ nal model 
because it was a better predictor of sequelae risk than 
mortality band and region. Heterogeneity was assessed 
by use of standard meta-analytic methods. 
Results
We selected 132 studies that were suitable for inclusion 
(ﬁ gure 1).14–145 The webappendix includes a full summary 
of the studies included. No unpublished data that satisﬁ ed 
our criteria were identiﬁ ed. Overall, 18 183 survivors of 
acute bacterial meningitis were examined for sequelae in 
the included studies (median number of survivors per 
study, 85 [IQR 47–148]). As shown in table 2, Hib was the 
most common cause of bacterial meningitis (35·5% of 
all the bacterial pathogens reported), followed by 
pneumococcus (19·6%), meningococcus (16·4%), and 
other pathogens (12·0%). Median age at meningitis 
episode was 29 months (IQR 13–67 months), and 
106 (79%) papers reported sequelae risk in children aged 
under 5 years. 
53 (40%) papers were from the European region, 
followed by the Americas (n=32), Eastern Mediterranean 
(n=10), Western Paciﬁ c (n=16), Africa (n=13), and Asia 
(n=8). The median (IQR) year of data collection was 1989 
See Online for webappendix
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(1982–94). Six (10%) post-discharge studies reported 
sequelae risk based on data collected after 2000. Studies 
with a retrospective design (n=58) were retained to avoid 
unnecessary loss of data, although diﬀ erences between 
retrospective and prospective studies were tested in the 
meta-regression analysis. The median follow-up time 
after hospital discharge was 24 months (IQR 6–63 months). 
Two studies followed individuals for 16 years after the 
meningitis episode.59,127 The median loss to follow-up 
(14·0% [IQR 7·8–22·7%]) was similar in all WHO regions 
and mortality strata. 
No studies reported sequelae risk in malnourished 
people. Two papers, from Malawi and South Africa, 
reported sequelae risk in HIV-infected children.69,112 
Both studies reported that sequelae risk was twice as 
high in HIV-infected than in non-HIV-infected children. 
We included the overall sequelae risk estimates (for 
HIV-infected and non-HIV-infected people) in our 
analysis. Sequelae risks were reported for all-cause 
bacterial meningitis (n=87), and for patients with only 
Hib (n=33), pneumococcal (n=27), and meningococcal 
meningitis (n=35). 
Table 3 shows risks of sequelae at discharge and post 
discharge. Total (major or minor) median (IQR) risks of 
sequelae were similar in studies with patients assessed at 
hospital discharge (22·8% [12·1–29·2%]) compared with 
those assessed during the post-discharge follow-up period 
(19·9% [12·3–35·3%]). In the post-discharge studies in 
which major (n=58) and minor (n=37) risks were included, 
the median (IQR) risks of at least one sequela were 12·8% 
(7·2–21·1%) and 8·6% (4·4–15·3%), respectively. 
The median (IQR) risk of at least one major sequela was 
24·7% (16·2–35·3%) in pneumococcal meningitis, 9·5% 
(7·1–15·3%) in Hib, and 7·2% (4·3–11·2%) in 
meningococcal meningitis (table 3). There was a 2·5 times 
greater risk of at least one major sequela in the nine studies 
that compared pneumococcal and Hib meningitis (risk 
ratio 2·49 [95% CI 1·87–3·31]).14,17,34,39,43,47,49,52,67 However, there 
were no signiﬁ cant diﬀ erences between meningococcal 
and Hib meningitis (risk ratio 0·92 [95% CI 0·66–1·29]).
Unadjusted and adjusted median (IQR) risks of the 
diﬀ erent types of major and minor sequelae are shown in 
table 3. Only 20 (15%) studies assessed all seven domains. 
30 (23%) studies only assessed hearing and 81 (61%) did 
not assess cognitive deﬁ cit. All domain-speciﬁ c risks 
were highest for pneumococcus, which was associated 
with a median (IQR) risk of major hearing loss of 9·9% 
(8·1–12·3%), which was higher than hearing loss due to 
Hib (4·5% [2·2–6·1%]) and meningococcus (4·1% 
[2·3–7·2%]). 
The most common types of major sequelae were hearing 
loss (33·6%), followed by seizures (12·6%), motor deﬁ cit 
(11·6%), cognitive impairment (9·1%), hydrocephalus 
(7·1%), and visual disturbance (6·3%). 470 (19·7%) 
individuals were reported to have multiple sequelae.  The 
most common multiple impairment combinations were 
cognitive deﬁ cit plus hearing loss (39·1%), cognitive 
deﬁ cit plus motor impairment (21·1%), and cognitive 
deﬁ cit plus motor deﬁ cit plus seizures (8·1%). 399 (85%) 
individuals were reported to have a cognitive deﬁ cit in 
combination with one or more other domains: 56·5% 
with a motor deﬁ cit, 61·1% with a hearing deﬁ cit. 
The risk of at least one major sequela was almost three 
times greater in the WHO African region (pooled risk 
estimate 25·1% [95% CI 18·9–32·0%]) and southeast 
Asian region (21·6% [95% CI 13·1–31·5%]) compared 
with the European region (9·4% [95% CI 7·0–12·3%]; 
ﬁ gure 2). There was also a progressively higher risk of 
major sequelae as WHO mortality strata increased 
(ﬁ gure 3); risk of a major sequela was three times greater 
in countries in the highest mortality stratum (stratum 
E, 29·1% [95% CI 20·9–37·9%]) than in those in the 
lowest stratum (stratum A, 9·1% [95% CI 7·2–11·1%]). 
Table 4 shows the results from the meta-regression 
analysis of the eﬀ ect of important covariates on the risk 
of at least one major sequelae. Because WHO region, 
WHO mortality band, and GNI were highly correlated, 
only GNI was included in the ﬁ nal analysis because it 
was a better predictor of sequelae risk than mortality 
band and region. Countries in the poorest GNI band 
(<US$1500 per head) had a much higher risk of major 
sequelae than the countries in the richest band (≥$45 000 
per head). The risk of a major sequela was also 
signiﬁ cantly higher in people aged less than 5 years 
compared with those aged 5 years or more. There were 
Studies (n) Median (IQR)
At discharge (total 42 studies)
Number of people with bacterial meningitis 42 101·0 (47·0–194·0)
Age at meningitis episode (months) 35 31·1 (13·1–50·0)
Cases laboratory conﬁ rmed (%) 42 100·0% (95·1–100·0%)
Pathogen identiﬁ ed (%)
Hib 19 31·1% (20·0–72·0%)
Pneumococcus 25 23·6% (14·1–40·2%)
Meningococcus 21 9·4% (5·1–32·1%)
Other pathogens 24 13·4% (8·2–28·1%)
Loss to follow-up (%) 42 0
Number of people examined for sequelae 42 84·5 (38·0–166·0)
Post discharge (total 90 studies)
Number of people with bacterial meningitis 90 89·0 (58·0–166·0)
Age at meningitis episode (months) 70 27·1 (13·8–72·4)
Cases laboratory conﬁ rmed (%) 90 100·0% (88·4–100·0%)
Pathogen identiﬁ ed (%)
Hib 46 40·0% (16·2–53·1%)
Pneumococcus 50 15·5% (10·0–21·0%)
Meningococcus 47 23·4% (12·1–42·1%)
Other pathogens 40 10·6% (4·1–20·0%)
Loss to follow-up (%) 37 14·1% (8·3–26·3%)
Number of people examined for sequelae 90 85·0 (48·0–138·0)
Hib=Haemophilus inﬂ uenzae type b.
Table 2: Study characteristics, by timing and pathogen
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no clear diﬀ erences in major sequelae risk associated 
with duration of follow-up, type of study design, 
percentage of isolates with laboratory conﬁ rmation, or 
decade of data collection. Additionally, a metaregression 
analysis of major sequelae risk by year of data collection 
from 1980 to 2008 revealed negligible correlation for all 
causes (coeﬃ  cient 0·0015, 95% CI −0·0051 to 0·0080) 
and speciﬁ c causes (Hib, 0·0030, −0·0073 to 0·0133; 
pneumococcus, 0·0079, 95% CI −0·0011 to 0·017; 
meningococcus, 0·0037, 95% CI −0·0023 to 0·0098). 
 All-cause at discharge Post discharge
All-cause Hib Pneumococcus Meningococcus
n Median (IQR) 
risk (%)
Adjusted 
median*
n Median (IQR) 
risk (%)
Adjusted 
median*
n Median (IQR) 
risk (%)
Adjusted 
median*
n Median (IQR) 
risk (%)
Adjusted 
median*
n Median (IQR) 
risk (%)
Adjusted 
median*
At least one sequela 
(major or minor)
28 22·8% 
(12·1–29·2%)
22·8% 59 19·9% 
(12·1–35·2%)
19·9% 27 14·5% 
(0·1–27·1%)
14·5% 20 34·7% 
(28·2–45·1%)
34·7% 27 9·5% 
(5·1–15·1%)
9·5%
Cognitive diﬃ  culties 7 2·3% 
(1·1–3·1%)
1·5% 21 2·8% 
(2·2–10%)
2·2% 11 1·6% 
(1·0–13·1%)
1·1% 9 6·3% 
(4·1–7·2%)
4·2% 6 2·9% 
(1·0–7·2%)
1·6%
Seizure disorder 5 5·4% 
(4·3–5·1%)
3·7% 27 2·0% 
(1·0–4·1%)
1·6% 9 2·2% 
(2·1–3·2%)
1·5% 8 3·7% 
(3·1–5·1%)
2·5% 5 0·9% 
(0·1–2·0%)
0·5%
Hearing loss 21 6·1% 
(3·1–17·1%)
4·1% 54 7·7% 
(3·1–13·2%)
6·0% 18 4·6% 
(3·1–8·2%)
3·2% 15 11·2% 
(9·1–19·2%)
7·5% 17 4·6% 
(3·0–7·3%)
2·6%
Motor deﬁ cit 9 6·6% 
(1·1–9·1%)
4·5% 30 3·0% 
(1·0–8·1%)
2·3% 14 3·2% 
(2·2–8·1%)
2·2% 8 8·7% 
(5·1–11·0%)
5·8% 9 1·8% 
(1·0–4·1%)
1·0%
Visual disturbance 2 4·1% 
(4·1–4·4%)
2·8% 14 1·2% 
(1·1–2·3%)
0·9% 2 0·7% 
(0·1–1·0%)
0·5% 5 1·7% 
(1·1–2·1%)
1·1% 4 2·7% 
(1·1–4·1%)
1·5%
Behavioural 
problems
1 1·0% 
(1·0–1·0%)
0·7% 5 3·3% 
(2·1–6·1%)
2·6% 2 3·0% 
(3·0–3·4%)
2·1% 2 6·8% 
(4·0–10·1%)
4·6% 2 1·0% 
(0·6–1·1%)
0·6%
Clinical impairments 7 2·5% 
(2·3–6·1%)
1·7% 11 1·1% 
(1·0–3·1%)
0·9% 3 1·7% 
(1·0–2·0%)
1·2% 1 5·1% 
(5·0–5·2%)
3·3% 1 0·4% 
(0·1–0·5%)
0·2%
Multiple 
impairments
28 5·5% 
(3·1–7·2%)
3·8% 27 4·4% 
(2·1–8·2%)
3·5% 24 3·7% 
(3·1–8·3%)
2·6% 20 8·6% 
(6·1–11·2%)
5·7% 25 2·3% 
(1·1–4·0%)
1·3%
At least one major 
sequela
28 16·0% 
(7·1–21·2%)
16·0% 58 12·8% 
(7·1–21·1%)
12·8% 27 9·5% 
(7·1–15·2%)
9·5% 20 24·7% 
(16·2–35·4%)
24·7% 26 7·2% 
(4·1–11·0%)
7·2%
Major cognitive 
diﬃ  culties
3 2·8% 
(2·3–3·3%)
2·0% 17 1·5% 
(1·2–2·2%)
1·1% 8 1·4% 
(1·0–2·1%)
1·0% 7 4·5% 
(4·1–6·2%)
3·1% 3 0·7% 
(0·0–3·1%)
0·4%
Major seizure 
disorder
5 5·4% 
(4·1–5·3%)
3·8% 27 2·0% 
(1·0–4·3%)
1·6% 11 2·1% 
(1·1–3·0%)
1·5% 8 3·7% 
(3·1–5·2%)
2·5% 5 0·9% 
(0·0–2·0%)
0·5%
Major hearing loss 21 5·9% 
(3·1–9·3%)
4·2% 54 5·6% 
(3·1–10·1%)
4·3% 19 4·5% 
(2·1–6·3%)
3·2% 15 9·9% 
(8·1–12·3%)
6·7% 16 3·8% 
(1·2–7·3%)
2·1%
Major motor deﬁ cit 9 1·2% 
(1·0–4·1%)
0·8% 29 2·0% 
(1·1–3·2%)
1·5% 14 1·7% 
(1·1–3·2%)
1·2% 7 4·8% 
(4·1–5·2%)
3·3% 9 1·4% 
(1·1–4·0%)
0·8%
Major visual 
disturbance
1 0·9% 
(1·0–1·0%)
0·7% 11 1·1% 
(1·1–2·3%)
0·8% 4 0·1% 
(0·1–0·1%)
0·1% 5 1·7% 
(1·0–2·3%)
1·1% 3 3·7% 
(2·1–4·2%)
2·1%
Major clinical 
impairments
7 2·5% 
(2·1–6·2%)
1·8% 11 1·1% 
(1·0–3·1%)
0·9% 4 1·0% 
(0·0–2·1%)
0·7% 1 5·0% 
(5·0–5·0%)
3·4% 1 0·4% 
(0·1–0·5%)
0·2%
Major multiple 
impairments
28 3·7% 
(2·1–6·1%)
2·6% 27 3·3% 
(2·1–5·2%)
2·5% 24 2·7% 
(2·0–4·1%)
1·9% 20 6·6% 
(3·1–9·4%)
4·5% 24 1·7% 
(1·0–2·1%)
1·0%
At least one minor 
sequela
17 9·4% 
(5·2–14·1%)
9·4% 37 8·6% 
(4·1–15·2%)
8·6% 17 5·7% 
(2·1–15·2%)
5·7% 10 18·6% 
(11·0–23·1%)
18·6% 11 2·3% 
(1·1–12·1%)
2·3%
Minor cognitive 
diﬃ  culties
4 2·1% 
(2·0–5·2%)
0·8% 13 4·8% 
(2·1–10%)
2·2% 6 8·8% 
(2·1–15·1%)
2·4% 4 5·1% 
(2·1–8·0%)
3·0% 3 7·1% 
(4·1–13·3%)
0·9%
Minor hearing loss 8 6·4% 
(1·0–9·1%)
2·7% 20 4·5% 
(3·1–7·1%)
2·1% 4 2·2% 
(2·1–3·2%)
0·6% 6 7·8% 
(6·1–12·1%)
4·6% 5 4·1% 
(1·1–5·0%)
0·5%
Minor motor deﬁ cit 4 7·6% 
(5·1–9·2%)
3·2% 10 3·0% 
(2·1–6·2%)
1·4% 7 4·8% 
(2·1–5·3%)
1·3% 5 4·6% 
(4·0–9·1%)
2·7% 1 3·0% 
(3·1–3·4%)
0·4%
Minor visual 
disturbance
2 3·6% 
(3·1–4·2%)
1·5% 4 1·0% 
(0·0–2·3%)
0·5% 1 0·1% 
(0·1–0·1%)
0·1% 1 3·1% 
(3·1–3·1%)
1·8% 1 1·8% 
(2·1–2·2%)
0·2%
Minor behavioural 
problems
1 1·0% 
(1·0–1·0%)
0·4% 5 3·3% 
(2·1–6·2%)
1·5% 2 3·0% 
(3·0–3·1%)
0·8% 2 6·8% 
(4·0–10·2%)
4·0% 2 1·0% 
(1·0–1·1%)
0·1%
Minor multiple 
impairments
17 2·1% 
(1·0–3·0%)
0·9% 27 1·9% 
(1·0–3·1%)
0·9% 14 2·0% 
(1·0–6·1%)
0·6% 10 4·0% 
(2·0–5·1%)
2·4% 9 1·3% 
(0·0–4·0%)
0·2%
*Median adjusted for incomplete reporting of mutually exclusive risk. Hib=Haemophilus inﬂ uenzae type b.
Table 3: Sequelae risk, by timing and pathogen
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European region: 24 studies
Dirdal14 1975 Denmark 245 59·1 0·13 (0·09–0·18)
Vienny15 1981 Switzerland 51 65·3 0·04 (0·0–0·11)
Schaad16 1982 Switzerland 78 65·3 0·15 (0·08–0·24)
Baselga17 1985 Spain 47 32 0·32 (0·20–0·46)
Fortnum18 1985 UK 202 45·4 0·07 (0·04–0·11)
Lutsar19 1986 Estonia 84 14·3 0·06 (0·02–0·12)
Kaaresen20 1986 Norway 88 87·1 0·16 (0·09–0·24)
Kilpi21 1987 Finland 276 48·1 0·07 (0·04–0·11)
Berg22 1988 Sweden 468 50·9 0·02 (0·01–0·04)
Kilpi23 1989 Finland 115 48·1 0·07 (0·03–0·12)
Duclaux24 1989 France 116 42·3 0·07 (0·03–0·12)
Katona25 1989 Hungary 109 12·8 0·37 (0·28–0·46)
Wilken26 1990 Germany 25 42·4 0·08 (0·01–0·22)
Lutschg27 1991 Switzerland 51 65·3 0·00 (0·00–0·04)
Palla28 1991 Italy 20 35·2 0·20 (0·06–0·40)
Oostenbrink29 1992 Netherlands 101 50·2 0·11 (0·06–0·18)
Francois30 1992 France 39 42·3 0·03 (0·00–0·10)
Biesheuvel31 1993 Netherlands 168 50·2 0·13 (0·08–0·18)
Koomen32 1993 Netherlands 680 50·2 0·12 (0·10–0·15)
Richardson33 1994 UK 124 45·4 0·02 (0·00–0·06)
Bedford34 1996 UK 1584 45·4 0·07 (0·06–0·09)
De Gans35 1997 Netherlands 119 50·2 0·20 (0·13–0·28)
Koomen36 1999 Netherlands 149 50·2 0·04 (0·01–0·08)
Ozen37 2003 Turkey 80 9·3 0·10 (0·04–0·17)
Subtotal (I2=87·9%, p<0·0001)    0·09 (0·07–0·12)
Region of the Americas: 9 studies
Pomeroy38 1975 USA 181 47·6 0·13 (0·09–0·19)
Dodge39 1975 USA 159 47·6 0·06 (0·03–0·10)
Munoz40 1979 Mexico 18 10 0·11 (0·01–0·29)
Jadavji41 1981 Canada 171 41·7 0·12 (0·07–0·17)
Lebel42 1983 USA 270 47·6 0·16 (0·12–0·21)
Letson43 1984 USA 51 47·6 0·16 (0·07–0·27)
Couto44 1992 Brazil 89 7·3 0·04 (0·01–0·10)
Wellman45 1995 Canada 68 41·7 0·09 (0·03–0·17)
Anjos46 2002 Brazil 19 7·3 0·21 (0·06–0·42)
Subtotal (I2=63·1%, p=0·006)    0·11 (0·08–0·15)
Eastern Mediterranean region: 7 studies
Shaltout47 1984 Kuwait 90 38·4 0·10 (0·05–0·17)
Zaki48 1984 Kuwait 83 38·4 0·23 (0·15–0·32)
Girgis49 1985 Egypt 177 1·8 0·04 (0·02–0·07)
Salih50 1985 Sudan 35 1·1 0·26 (0·13–0·41)
Salih51 1986 Sudan 27 1·1 0·22 (0·09–0·39)
Daoud52 1991 Jordan 106 3·3 0·20 (0·13–0·28)
Farag53 2002 Egypt 202 1·8 0·07 (0·04–0·11)
Subtotal (I2=85·2%, p<0·0001)    0·14 (0·08–0·22)
Western Paciﬁc region: 8 studies
Dawson54 1981 New Zealand 139 27·9 0·05 (0·02–0·09)
Jiang55 1983 China 60 2·8 0·12 (0·05–0·21)
Grimwood56 1985 Australia 109 40·3 0·08 (0·04–0·14)
Carroll57 1990 Vanuatu 65 2·3 0·35 (0·24–0·47)
Yeat58 1991 Malaysia 33 7 0·15 (0·05–0·29)
Chang59 1995 China 113 2·8 0·26 (0·18–0·34)
Wang60 1997 Taiwan 98 2·8 0·02 (0·00–0·06)
Wandi61 2002 PNG 80 1 0·34 (0·24–0·44)
Subtotal (I2=91·7%, p<0·0001)    0·15 (0·07–0·25)
South-East Asian region: 3 studies
Gupta62 1991 India 24 1·1 0·17 (0·05–0·34)
Singhi63 1993 India 80 1·1 0·30 (0·21–0·40)
George64 1994 India 100 1·1 0·17 (0·10–0·25)
Subtotal (I2=57·5%, p=0·095)    0·22 (0·13–0·32)
African region: 7 studies
Ford65 1991 Swaziland 51 2·5 0·37 (0·25–0·51)
Akpede66 1992 Nigeria 50 1·2 0·32 (0·20–0·45)
Goetghebuer67 1993 Gambia 73 0·4 0·19 (0·11–0·29)
Hodgson68 1998 Ghana 505 0·7 0·16 (0·13–0·19)
Molyneux69 1999 Malawi 248 0·3 0·31 (0·26–0·37)
Melaku70 2000 Ethiopia 136 0·3 0·21 (0·15–0·29)
Pitkaranta71 2005 Angola 131 3·5 0·26 (0·19–0·34)
Subtotal (I2=82·7%, p<0·0001)    0·25 (0·19–0·32)
Heterogeneity between groups p<0·0001   
Overall (I2=89·5%, p<0·0001)    0·13 (0·11–0·16)
 Study date Country n GNI Proportion (95% CI)     
0 0·30·20·1 0·4
Proportion with at least one major sequela
0·5
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Discussion
We reported a median overall risk of long-term disabling 
sequelae in meningitis survivors after discharge from 
hospital of 20%. Risks of at least one major post discharge 
sequela ranged from 9% to 25% across the WHO regions, 
and were almost three times higher in Africa and Asia 
than in Europe. Major sequelae risk also increased 
signiﬁ cantly as GNI per head decreased. The overall 
global risk was similar to that found in previous reviews,1,4 
but our study diﬀ ered by reporting disparities in risk 
between high-income and low-income countries. 
Hearing loss was the most common type of sequela. 
Motor deﬁ cit, seizures, and cognitive deﬁ cits were also 
important. 20% of the impairments were reported to 
involve multiple domains; cognitive deﬁ cit plus hearing 
loss or motor deﬁ cit was the most commonly reported 
combination. Paediatricians are well aware that bacterial 
meningitis can result in complex, multifaceted syndromes; 
parenchymal brain injury can result in normal structural 
appearance, diﬀ use oedema, focal lesions, and gross 
cerebral necrosis.13 However, no other studies have 
reported such high risks of multiple impairments from 
bacterial meningitis. The distribution of the diﬀ erent 
types of sequelae seemed similar for Hib, pneumococcus, 
and meningococcus, suggesting that the organisms might 
cause similar intracranial pathological processes. 
Long-term disabling sequelae were particularly 
common in people with pneumococcal meningitis. This 
has been reported in other studies,1,4,130 and is due to the 
particular virulence of the pneumococcal organism.13 Hib 
was the most common cause of bacterial meningitis, 
because many studies included data from the pre-Hib-
vaccination era. The risks of sequelae for Hib and 
meningococcal meningitis diﬀ ered little. 
There also seems to have been little change in the risk of 
long-term disabling sequelae over the past three decades. 
In particular, there was no change in risk over time for 
speciﬁ c causes (Hib, pneumococcus, and meningococcus). 
This might be due to the increased use of highly sensitive 
tests to diagnose long-term disabling sequelae. An 
alternative explanation is that advances in medical care 
and new technologies (which should be reducing sequelae 
risk) are not reaching the people most in need. Further 
research and investigation into these issues is needed. 
Our review had several limitations. First, only 60% of 
studies were prospective, and almost 20% of individuals 
in these studies were lost to follow-up. Families of disabled 
people might be more likely to suﬀ er from ﬁ nancial or 
emotional stresses than families of non-disabled people, 
and so might be more likely to move or migrate out of the 
study area and become lost to follow-up.146 Conversely, 
those who have few or no sequelae might be more likely 
to become lost to follow-up due to lack of interest in the 
study or no perceived beneﬁ t in continued participation. 
Additionally, disabled people have a higher mortality risk 
than non-disabled people, and some will have died before 
follow-up, leaving the survivors with a spuriously low 
occurrence of sequelae.146 This survivor bias is particularly 
important for African and Asian countries with high case 
fatality after hospital discharge.147 Furthermore, all studies 
included in our study were hospital based. Hospital 
studies are biased towards patients with better access to 
acute and long-term health care.148 These people tend to 
have higher socioeconomic status and lower sequelae risk 
than those with poor access to care.4
Second, our studies were very heterogeneous and this 
was obvious in our metaregression analysis. This was 
due to the wide range of data sources retained, particularly 
in studies from low-income countries. However, we did 
adjust our meta-analyses for important variables (ie, age, 
study design, GNI, duration of follow-up, year of data 
collection, percentage of cases laboratory conﬁ rmed) and 
presented both unadjusted and adjusted estimates. 
Third, observational studies are prone to problems with 
misclassiﬁ cation.149 Only 15% of the studies examined all 
the sequelae domains; thus, the number of individuals with 
multiple impairments is likely to have been underestimated. 
Moreover, only two studies assessed cognitive and visual 
domains in the African and Asian regions, and these risks 
are likely to have been underestimated. However, our 
abstractors used strict case deﬁ nitions, and we adjusted the 
domain-speciﬁ c sequelae so that they represented mutually 
exclusive counts of children.
Finally, few studies assessed the inﬂ uence of important 
potential risk factors. No studies documented the eﬀ ect 
of malnutrition and only two studies examined the role 
Figure 2: Meta-analysis of the risk of developing at least one major post-
discharge sequela by study and WHO region (all-cause meningitis)
Analysis was by random-eﬀ ects meta-analysis. GNI=gross national income.
Figure 3: Meta-analysis estimates of the risk of developing at least one major post-discharge sequela by WHO 
mortality strata (all-cause meningitis)
Analysis was by random-eﬀ ects meta-analysis. Mortality strata were created by WHO11 to deﬁ ne countries in terms 
of health status and mortality rather than income: A=very low child mortality; B=low child mortality plus low adult 
mortality; C=low child mortality plus high adult mortality; D=high child mortality plus high adult mortality; E=high 
child mortality plus very high adult mortality.
A: 29 studies
Subtotal ( I2=82·8%, p<0·0001) 0·09 (0·07–0·11)
B: 13 studies
Subtotal ( I2=86·1%, p<0·0001) 0·16 (0·10–0·23)
C: 2 studies
Subtotal ( I2=96·8%, p<0·0001) 0·19 (0·00–0·56)
D: 11 studies
Subtotal ( I2=86·7%, p<0·0001) 0·18 (0·12–0·24)
E: 3 studies
Subtotal ( I2=69·5%, p=0·038) 0·29 (0·21–0·38)
Heterogeneity between groups: p<0·0001
Overall ( I2=89·5%, p<0·0001) 0·13 (0·11–0·16)
Proportion (95% CI) 
0 0·30·20·1 0·4
Proportion with at least one major sequela
0·5
324 www.thelancet.com/infection   Vol 10   May 2010
Review
of HIV in the development of neurodevelopmental 
sequelae. We were not able to examine the eﬀ ect of other 
important risk factors, such as prematurity or low birth 
weight, because few studies provided suﬃ  cient data to 
examine these issues separately. We were also unable to 
report on the underlying level of neurodevelopmental 
disability in speciﬁ c regions because most studies did 
not report disability risk in healthy community control 
groups, nor the developmental status of participants 
before the acute attack of meningitis.
Our analyses focused on the risk of major sequelae in 
patients after they were discharged home from hospital. 
The natural healing process after the acute meningitis 
episode leads clinicians to expect a decrease in the 
proportion of people with sequelae from bacterial 
meningitis over time. However, we found little change 
in sequelae risk during the post-discharge follow-up 
period. Other systematic reviews have also reported 
similar ﬁ ndings,1 and this might be due to problems 
with sequelae ascertainment in the included studies. 
Indeed, the longer the follow-up period, the longer the 
time available for disabled people to migrate or die or 
refuse to participate (ie, become lost to follow-up). 
Additionally, as people (especially children) become 
older, they become easier to examine and several 
sequelae that are not able to be ascertained in younger 
people can become evident at an older age (eg, motor 
impairments can manifest as ﬂ oppiness in infants but 
spasticity in older children, tests for cognitive deﬁ cits 
and hearing loss are very diﬃ  cult to administer in young 
children). Prospective studies with long-term follow-up 
and repeat examinations of the same people provide the 
most useful data. A large prospective UK study reported 
that almost 16% of children followed up to age 5 years 
had a signiﬁ cant disability.34 Studies from Australia and 
the UK reported up to 12% of children with major 
Studies 
(n)
Participants 
(N)
Pooled risk within each 
subgroup (95% CI)
Bivariate meta-regression Multivariate meta-regression
Diﬀ erence in risk from 
most prevalent stratum*
p† Diﬀ erence in risk from 
most prevalent stratum*‡
p†
Gross national income (US$ per head)
>45 000 20 5160 0·088 (0·067–0·113) .. .. .. ..
25 000–44 999 11 907 0·109 (0·071–0·154) 0·022 0·45 −0·11 0·06
5000–24 999 7 432 0·135 (0·054–0·247) 0·046 0·21 0·047 0·18
1500–4999 9 1003 0·164 (0·086–0·260) 0·073 0·031 0·07 0·028
<1500 11 1358 0·238 (0·190–0·290) 0·150 0·000 0·15 0·000
Data collection period
1970–1979 4 603 0·105 (0·066–0·153) −0·034 0·51 0·054 0·21
1980–1989 22 2846 0·117 (0·084–0·155) −0·022 0·44 0·5 0·81
1990–1999 26 4763 0·139 (0·104–0·178) .. .. .. ..
2000–2006 6 648 0·187 (0·103–0·289) 0·048 0·34 −0·026 0·42
Age-group
<5 years 52 8135 0·140 (0·117–0·165) .. .. .. ..
>5 years 6 725 0·072 (0·017–0·163) −0·068 0·072 −0·057 0·017
Study design
Prospective 42 6261 0·142 (0·112–0·175) .. .. .. ..
Retrospective 16 2599 0·109 (0·082–0·140) −0·033 0·27 −0·001 0·95
Duration of follow-up
<1 year 22 2651 0·116 (0·079–0·159) .. .. .. ..
1–1·9 years 8 629 0·137 (0·107–0·171) 0·021 0·53 0·054 0·09
2–4·9 years 11 1342 0·230 (0·165–0·301) 0·114 0·004 −0·005 0·86
5–9·9 years 10 2458 0·099 (0·065–0·140) −0·017 0·68 −0·044 0·07
>10 years 7 1780 0·097 (0·049–0·159) −0·019 0·60 0·01 0·70
Percentage of cases laboratory conﬁ rmed
100% 32 4723 0·097 (0·077–0·120) .. .. .. ..
80–99% 7 873 0·114 (0·047–0·204) 0·017 0·60 −0·009 0·73
60–79% 8 2071 0·232 (0·125–0·360) 0·135 0·001 0·0118 0·001
40–59% 3 147 0·312 (0·240–0·389) 0·215 0·003 0·0180 0·01
0–39% 7 915 0·159 (0·095–0·235) 0·062 0·10 −0·005 0·88
*Compared to the most prevalent stratum. †Student’s t-test for diﬀ erence from the most prevalent stratum. ‡Adjusted for GNI band, data collection period, age-group, study 
design, duration of follow-up, percentage of cases laboratory conﬁ rmed.
Table 4: Metaregression analysis of the eﬀ ect of important explanatory variables on the risk of major post discharge sequelae (all-cause meningitis)
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impairments and 30% of children with cognitive and 
behavioural problems at 12 years after the meningitis 
episode.57,98 However, an older US study reported a sharp 
decrease in neurological and audiological abnormalities 
as duration of follow-up increased (42% of children at 
hospital discharge, 38% at 1 month, and 5% at 12 months 
after the acute meningitis episode).150 
We also reported that the risk of sequelae in children 
aged less than 5 years was twice as high as for older 
people. This ﬁ nding is consistent with other studies that 
used multivariate regression models and reported 
increased odds of meningitis sequelae in infants 
compared to older people.151 Other researchers have 
described high risk of sequelae in infants who develop 
acute bacterial meningitis in the early months of life.4,34,152 
This study has important implications for policy 
development. We have emphasised the diﬀ erentials in 
the risk of sequelae after bacterial meningitis between 
high-income and low-income countries. There are many 
reasons for these disparities, including delay in receiving 
eﬀ ective hospital antibiotic treatment for the acute 
meningitis episode.21,153 People in low-income countries 
often have to travel much further to a health-care facility 
than those in high-income countries.154 Costs of hospital 
care can be prohibitive for many families and might 
result in signiﬁ cant delays in presentation to hospital.154 
There is also an increasing problem of suboptimum 
quality of care once people are admitted to hospital in 
low-income countries.155 Reasons include emerging 
antibiotic resistance and increased use of low-cost generic 
parenteral antibiotics of low potency (ie, third-generation 
cephalosporins).155,156 Treatment failures from prescribed 
antibiotics are becoming increasingly common and must 
be addressed by tighter manufacturing regulations.156
The results of this study highlight the importance of 
both primary and secondary prevention. Many of the 
reported disabilities could have been averted. Highly 
eﬃ  cacious conjugate vaccines are now available for the 
three major causes of bacterial meningitis in children aged 
less than 5 years (Hib, pneumococcus, and meningococcus). 
Vaccines for other important causes of meningitis are also 
needed (eg, group B streptococcus). Additionally, timely 
access to follow-up services for disabled people (such as 
antiepileptics, hearing assessment, speech therapy, 
physiotherapy, and occupational therapy) can reduce the 
severity of sequelae and improve quality of life.2 However, 
these services are often not available in low-income 
countries. For example, a recent study in Senegal reported 
that no children with bacterial meningitis received post-
discharge follow-up care from a health-care professional 
12 months after the acute bacterial meningitis episode 
(Griﬃ  ths UK, unpublished). All people who are admitted 
to hospital with a serious neurological infection such as 
bacterial meningitis require close long-term follow-up after 
hospital discharge.13 Inpatient hospital audit and peer 
review has improved markedly over the past decade,157 but 
post-discharge care has not received the same attention. 
Global, regional, and national estimates should be 
revised to indicate the true burden of long-term disabling 
sequelae from bacterial meningitis. These data should be 
disseminated so that appropriate services and follow-up 
care can be planned and implemented. This information 
should also be used in advocacy to improve basic services 
such as vaccination, timely access to hospital care, 
hospital treatment, and long-term community-based 
follow-up for people with meningitis sequelae. 
Contributors
KE took the lead role in the design and conceptualisation of all aspects of 
this study, was the second data abstractor on the paper, oversaw the 
study’s conduct, wrote all drafts of the paper, and was responsible for the 
ﬁ nal version. AC assisted in the conceptualisation of the methods and 
results sections, designed the data analysis plan, did much of the data 
analysis, and provided substantial inputs into all versions of the paper. 
VSK designed all the literature searches, created the data abstraction 
forms, was the ﬁ rst data abstractor, and provided substantial inputs into 
all versions of the paper. CS commented on diﬀ erent drafts of the paper 
and was responsible for the meta-analyses. UKG conceived the initial 
idea for this study and provided inputs into all versions of the paper. IR 
provided important objective advice about the design, conduct, analyses, 
and synthesis of the study, and provided substantial inputs into the ﬁ nal 
versions of the paper. All authors approved the ﬁ nal version.
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest.
Acknowledgments
Funding for this study was provided by the WHO Child Health 
Epidemiology Reference Group and the Global Alliance for Vaccine 
Initiative (GAVI). KE, AC, VSK, and UKG were members of GAVI’s Hib 
Initiative operational team. IR is a member of the Child Health 
Epidemiology Reference Group. 
References
1 Baraﬀ  LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in 
children: a meta-analysis. Pediatr Infect Dis J 1993; 12: 389–94.
2 Mercer SW, MacDonald R. Disability and human rights. Lancet 
2007; 370: 548–49.
3 Mont D. Measuring health and disability. Lancet 2007; 369: 1658–63.
4 Carter JA, Neville BG, Newton CR. Neuro-cognitive impairment 
following acquired central nervous system infections in childhood: 
a systematic review. Brain Res Rev 2003; 43: 57–69.
5 Lim SS, Stein DB, Charrow A, Murray CJ. Tracking progress 
towards universal childhood immunisation and the impact of 
global initiatives: a systematic analysis of three-dose diphtheria, 
tetanus, and pertussis immunisation coverage. Lancet 2008; 
372: 2031–46.
6 Johnson HL, Liu L, Fischer-Walker C, Black RE. Estimating the 
distribution of causes of death among children age 1–59 months in 
high mortality countries with incomplete death certiﬁ cation. 
Int J Epidemiol (in press).
7 Watt JP, Wolfson LJ, O’Brien KL, et al. Burden of disease caused by 
Haemophilus inﬂ uenzae type b in children younger than 5 years: 
global estimates. Lancet 2009; 374: 903–11.
8 O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by 
Streptococcus pneumoniae in children younger than 5 years: global 
estimates. Lancet 2009; 374: 893–902.
9 WHO. The global burden of disease: a comprehensive assessment 
of mortality and disability from diseases, injuries and risk factors in 
1990 and projected to 2020. Cambridge, MA: Harvard University 
Press, 2001.
10 WHO Collaborating Centres for Classiﬁ cation of Diseases. 
International statistical classiﬁ cation of diseases and related health 
problems (ICD-10): volume 1 (10th edn). Geneva: WHO, 1992.
11 WHO. List of member states by WHO region and mortality 
stratum. http://www.who.int/whr/2003/en/member_
states_182-184_en.pdf (accessed Mar 11, 2010).
12 Kim KS. Acute bacterial meningitis in infants and children. 
Lancet Infect Dis 2010; 10: 32–42.
Search strategy 
and selection 
criteria
These are described 
in detail in the 
Methods section.
326 www.thelancet.com/infection   Vol 10   May 2010
Review
13 Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson 
textbook of pediatrics (18th edn). Philidelphia: Saunders Elsevier, 2007. 
14 Dirdal M, Adeler A, Andersen EN, et al. Purulent meningitis in 
children. Mortality and sequelae. Ugeskr Laeger 1981; 143: 1689–93 
(in Danish).
15 Vienny H, Despland PA, Lutschg J, Deonna T, Dutoit-Marco ML, 
Gander C. Early diagnosis and evolution of deafness in childhood 
bacterial meningitis: a study using brainstem auditory evoked 
potentials. Pediatrics 1984; 73: 579–86.
16 Schaad UB, Krucko J, Pfenninger J. An extended experience with 
cefuroxime therapy of childhood bacterial meningitis. 
Pediatr Infect Dis 1984; 3: 410–16.
17 Baselga Asensio C, Ramos Fuentes FJ, Gracia Casanova M, et al. 
Cortical evoked auditory evoked potentials in a series of patients 
who had bacterial meningitis during childhood. An Esp Pediatr 1987; 
27: 339–42 (in Spanish).
18 Fortnum H, Davis A. Hearing impairment in children after 
bacterial meningitis: incidence and resource implications. 
Br J Audiol 1993; 27: 43–52.
19 Lutsar I, Siirde T, Soopold T. Long term follow-up of Estonian children 
after bacterial meningitis. Pediatr Infect Dis J 1995; 14: 624–25.
20 Kaaresen PI, Flaegstad T. Prognostic factors in childhood bacterial 
meningitis. Acta Paediatr 1995; 84: 873–78.
21 Kilpi T, Anttila M, Kallio MJ, Peltola H. Length of prediagnostic 
history related to the course and sequelae of childhood bacterial 
meningitis. Pediatr Infect Dis J 1993; 12: 184–88.
22 Berg S, Trollfors B, Hugosson S, Fernell E, Svensson E. Long-term 
follow-up of children with bacterial meningitis with emphasis on 
behavioural characteristics. Eur J Pediatr 2002; 161: 330–36.
23 Kilpi T, Peltola H, Jauhiainen T, Kallio MJ. Oral glycerol and 
intravenous dexamethasone in preventing neurologic and 
audiologic sequelae of childhood bacterial meningitis. The Finnish 
Study Group. Pediatr Infect Dis J 1995; 14: 270–78.
24 Duclaux R, Sevin F, Ferber C, Drai MF, Dubreuil C. Brainstem 
auditory evoked potentials following meningitis in children. 
Brain Dev 1993; 15: 340–45.
25 Katona G, Farkas Z, Hirschberg J, Hajdi G, Nyerges G. Hearing loss 
resulting from purulent meningitis in the light of adjuvant 
dexamethasone therapy. Orv Hetil 1993; 134: 247–49 (in Hungarian).
26 Wilken B, van Wees J, Tegtmeyer FK, Aksu F. Hearing disorders in 
children less than 16 months of age after bacterial meningitis with 
reference to cerebrospinal ﬂ uid elastase. Klin Padiatr 1995; 
207: 12–16 (in German).
27 Lutschg J. Hearing disorders in meningitis. Antibiot Chemother 
1992; 45: 218–25.
28 Palla G, Villirillo A, Ughi C, Berrettini S, Sellari Franceschini S, 
Ursino F. Sequelae of bacterial meningitis in childhood: a study of 
hearing impairment. Minerva Pediatr 1995; 47: 401–08 (in Italian).
29 Oostenbrink R, Maas M, Moons KG, Moll HA. Sequelae after 
bacterial meningitis in childhood. Scand J Infect Dis 2002; 34: 379–82.
30 Francois M, Laccourreye L, Huy ET, Narcy P. Hearing impairment 
in infants after meningitis: detection by transient evoked 
otoacoustic emissions. J Pediatr 1997; 130: 712–17.
31 Biesheuvel CJ, Koomen I, Vergouwe Y, et al. Validating and 
updating a prediction rule for neurological sequelae after childhood 
bacterial meningitis. Scand J Infect Dis 2006; 38: 19–26.
32 Koomen I, Grobbee DE, Roord JJ, et al. Prediction of academic and 
behavioural limitations in school-age survivors of bacterial 
meningitis. Acta Paediatr 2004; 93: 1378–85.
33 Richardson M, Williamson T, Reid A, Tarlow M, Rudd P. Testing for 
hearing loss after meningitis. J Pediatr 1998; 132: 749–50.
34 Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. 
Meningitis in infancy in England and Wales: follow up at age 
5 years. BMJ 2001; 323: 533–36.
35 de Gans J, van de Beek D. Dexamethasone in adults with bacterial 
meningitis. N Engl J Med 2002; 347: 1549–56.
36 Koomen I, van Furth AM, Kraak MA, Grobbee DE, Roord JJ, 
Jennekens-Schinkel A. Neuropsychology of academic and 
behavioural limitations in school-age survivors of bacterial 
meningitis. Dev Med Child Neurol 2004; 46: 724–32.
37 Ozen M, Kanra G, Kara A, et al. Long-term beneﬁ cial eﬀ ects of 
dexamethasone on intellectual and neuropsychological outcome of 
children with pneumococcal meningitis. Scand J Infect Dis 2006; 
38: 104–09.
38 Pomeroy SL, Holmes SJ, Dodge PR, Feigin RD. Seizures and other 
neurologic sequelae of bacterial meningitis in children. 
N Engl J Med 1990; 323: 1651–57.
39 Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of 
hearing impairment as a sequela of acute bacterial meningitis. 
N Engl J Med 1984; 311: 869–74.
40 Munoz AI. Bacterial meningitis in pediatric patients: a ﬁ ve-year 
experience. Bol Asoc Med P R 1982; 74: 62–65.
41 Jadavji T, Biggar WD, Gold R, Prober CG. Sequelae of acute 
bacterial meningitis in children treated for seven days. Pediatrics 
1986; 78: 21–25.
42 Lebel MH, McCracken GH Jr. Delayed cerebrospinal ﬂ uid 
sterilization and adverse outcome of bacterial meningitis in infants 
and children. Pediatrics 1989; 83: 161–67.
43 Letson GW, Gellin BG, Bulkow LR, Parks DJ, Ward JI. Severity and 
frequency of sequelae of bacterial meningitis in Alaska Native 
infants. Correlation with a scoring system for severity of sequelae. 
Am J Dis Child 1992; 146: 560–66.
44 Couto MI, Monteiro SR, Lichtig I, Casella EB, Carvallo RM, de 
Navarro JM. Audiological assessment and follow-up after bacterial 
meningitis. Arq Neuropsiquiatr 1999; 57: 808–12 (in Portuguese).
45 Wellman MB, Sommer DD, McKenna J. Sensorineural hearing loss 
in postmeningitic children. Otol Neurotol 2003; 24: 907–12.
46 Anjos LP, Queiros F, Pereira MC, Brandao M, Melo A, Lucena R. 
Audiologic late prognosis due to meningitis in children. 
Arq Neuropsiquiatr 2004; 62: 635–40 (in Portuguese).
47 Shaltout AA, Auger LT, Awadallah NB, et al. Morbidity and mortality 
of bacterial meningitis in Arab children. J Trop Med Hyg 1989; 
92: 402–06.
48 Zaki M, Daoud AS, al-Saleh Q, West PW. Childhood bacterial 
meningitis in Kuwait. J Trop Med Hyg 1990; 93: 7–11.
49 Girgis NI, Farid Z, Mikhail IA, Farrag I, Sultan Y, Kilpatrick ME. 
Dexamethasone treatment for bacterial meningitis in children and 
adults. Pediatr Infect Dis J 1989; 8: 848–51.
50 Salih MA, el Hag AI, Sid Ahmed H, et al. Endemic bacterial 
meningitis in Sudanese children: aetiology, clinical ﬁ ndings, 
treatment and short-term outcome. Ann Trop Paediatr 1990; 
10: 203–10.
51 Salih MA, Khaleefa OH, Bushara M, et al. Long term sequelae of 
childhood acute bacterial meningitis in a developing country. 
A study from the Sudan. Scand J Infect Dis 1991; 23: 175–82.
52 Daoud AS, al-Sheyyab M, Batchoun RG, Rawashdeh MO, Nussair 
MM, Pugh RN. Bacterial meningitis: still a cause of high mortality 
and severe neurological morbidity in childhood. J Trop Pediatr 1995; 
41: 308–10.
53 Farag HF, Abdel-Fattah MM, Youssri AM. Epidemiological, clinical 
and prognostic proﬁ le of acute bacterial meningitis among children 
in Alexandria, Egypt. Indian J Med Microbiol 2005; 23: 95–101.
54 Dawson KP, Abbott GD, Mogridge N. Bacterial meningitis in 
childhood: a 13 year review. N Z Med J 1988; 101: 758–60.
55 Jiang ZD, Liu XY, Wu YY, Zheng MS, Liu HC. Long-term 
impairments of brain and auditory functions of children 
recovered from purulent meningitis. Dev Med Child Neurol 1990; 
32: 473–80.
56 Grimwood K, Anderson P, Anderson V, Tan L, Nolan T. Twelve year 
outcomes following bacterial meningitis: further evidence for 
persisting eﬀ ects. Arch Dis Child 2000; 83: 111–16.
57 Carroll KJ, Carroll C. A prospective investigation of the long-term 
auditory-neurological sequelae associated with bacterial meningitis: 
a study from Vanuatu. J Trop Med Hyg 1994; 97: 145–50.
58 Yeat SW, Mukari SZ, Said H, Motilal R. Post meningitic sensori-
neural hearing loss in children—alterations in hearing level. 
Med J Malaysia 1997; 52: 285–90.
59 Chang CJ, Chang HW, Chang WN, et al. Seizures complicating 
infantile and childhood bacterial meningitis. Pediatr Neurol 2004; 
31: 165–71.
60 Wang KW, Chang WN, Chang HW, et al. The signiﬁ cance of seizures 
and other predictive factors during the acute illness for the long-term 
outcome after bacterial meningitis. Seizure 2005; 14: 586–92.
61 Wandi F, Kiagi G, Duke T. Long-term outcome for children with 
bacterial meningitis in rural Papua New Guinea. J Trop Pediatr 
2005; 51: 51–53.
62 Gupta V. Hearing evaluation in children with bacterial meningitis. 
Indian Pediatr 1993; 30: 1175–79.
www.thelancet.com/infection   Vol 10   May 2010 327
Review
63 Singhi P, Bansal A, Geeta P, Singhi S. Predictors of long term 
neurological outcome in bacterial meningitis. Indian J Pediatr 2007; 
74: 369–74.
64 George CN, Letha S, Bai SS. A clinical study of chronic morbidity in 
children following pyogenic meningitis. Indian Pediatr 2002; 
39: 663–67.
65 Ford H, Wright J. Bacterial meningitis in Swaziland: an 18 month 
prospective study of its impact. J Epidemiol Community Health 1994; 
48: 276–80.
66 Akpede GO, Akuhwa RT, Ogiji EO, Ambe JP. Risk factors for an 
adverse outcome in bacterial meningitis in the tropics: a reappraisal 
with focus on the signiﬁ cance and risk of seizures. 
Ann Trop Paediatr 1999; 19: 151–59.
67 Goetghebuer T, West TE, Wermenbol V, et al. Outcome of 
meningitis caused by Streptococcus pneumoniae and Haemophilus 
inﬂ uenzae type b in children in The Gambia. Trop Med Int Health 
2000; 5: 207–13.
68 Hodgson A, Smith T, Gagneux S, et al. Survival and sequelae of 
meningococcal meningitis in Ghana. Int J Epidemiol 2001; 
30: 1440–46.
69 Molyneux EM, Tembo M, Kayira K, et al. The eﬀ ect of HIV infection 
on paediatric bacterial meningitis in Blantyre, Malawi. 
Arch Dis Child 2003; 88: 1112–18.
70 Melaku A. Sensorineural hearing loss in children with epidemic 
meningococcal meningitis at Tikur Anbessa Hospital. Ethiop Med J 
2003; 41: 113–21.
71 Pitkaranta A, Pelkonen T, de Sousa ESMO, Bernardino L, Roine I, 
Peltola H. Setting up hearing screening in meningitis children in 
Luanda, Angola. Int J Pediatr Otorhinolaryngol 2007; 71: 1929–31.
72 Akpede GO. Presentation and outcome of sporadic acute bacterial 
meningitis in children in the African meningitis belt: recent 
experience from northern Nigeria highlighting emergent factors in 
outcome. West Afr J Med 1995; 14: 217–26.
73 Almuneef M, Memish Z, Khan Y, Kagallwala A, Alshaalan M. 
Childhood bacterial meningitis in Saudi Arabia. J Infect 1998; 
36: 157–60.
74 Anh DD, Kilgore PE, Kennedy WA, et al. Haemophilus inﬂ uenzae 
type B meningitis among children in Hanoi, Vietnam: 
epidemiologic patterns and estimates of H. inﬂ uenzae type B 
disease burden. Am J Trop Med Hyg 2006; 74: 509–15.
75 Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter 
surveillance of pneumococcal meningitis in children: clinical 
characteristics, and outcome related to penicillin susceptibility and 
dexamethasone use. Pediatrics 1998; 102: 1087–97.
76 Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired 
bacterial meningitis: risk stratiﬁ cation for adverse clinical outcome 
and eﬀ ect of antibiotic timing. Ann Intern Med 1998; 129: 862–69.
77 Baldwin RL, Sweitzer RS, Freind DB. Meningitis and sensorineural 
hearing loss. Laryngoscope 1985; 95: 802–05.
78 Barquet N, Domingo P, Cayla JA, et al. Meningococcal disease in a 
large urban population (Barcelona, 1987–1992): predictors of dismal 
prognosis. Arch Intern Med 1999; 159: 2329–40.
79 Bent JP 3rd, Beck RA. Bacterial meningitis in the pediatric 
population: paradigm shifts and ramiﬁ cations for otolaryngology-
head and neck surgery. Int J Pediatr Otorhinolaryngol 1994; 30: 41–49.
80 Berlow SJ, Caldarelli DD, Matz GJ, Meyer DH, Harsch GG. 
Bacterial meningitis and sensorineural hearing loss: a prospective 
investigation. Laryngoscope 1980; 90: 1445–52.
81 Bohr V, Paulson OB, Rasmussen N. Pneumococcal meningitis. Late 
neurologic sequelae and features of prognostic impact. Arch Neurol 
1984; 41: 1045–49.
82 Broughton SJ, Warren RE. A review of Haemophilus inﬂ uenzae 
infections in Cambridge 1975–1981. J Infect 1984; 9: 30–42.
83 Brouwer MC, van de Beek D, Heckenberg SG, Spanjaard L, 
de Gans J. Community-acquired Haemophilus inﬂ uenzae meningitis 
in adults. Clin Microbiol Infect 2007; 13: 439–42.
84 Bruyn GA, Kremer HP, de Marie S, Padberg GW, Hermans J, 
van Furth R. Clinical evaluation of pneumococcal meningitis in 
adults over a twelve-year period. Eur J Clin Microbiol Infect Dis 1989; 
8: 695–700.
85 Casado-Flores J, Aristegui J, de Liria CR, Martinon JM, 
Fernandez C. Clinical data and factors associated with poor 
outcome in pneumococcal meningitis. Eur J Pediatr 2006; 
165: 285–89.
86 Casella EB, Cypel S, Osmo AA, et al. Sequelae from meningococcal 
meningitis in children: a critical analysis of dexamethasone therapy. 
Arq Neuropsiquiatr 2004; 62: 421–28.
87 Cherian B, Singh T, Chacko B, Abraham A. Sensorineural hearing 
loss following acute bacterial meningitis in non-neonates. 
Indian J Pediatr 2002; 69: 951–55.
88 Damodaran A, Aneja S, Malhotra VL, Bais AS, Ahuja B, Taluja V. 
Sensorineural hearing loss following acute bacterial 
meningitis—a prospective evaluation. Indian Pediatr 1996; 
33: 763–66.
89 D’Angio CT, Froehlke RG, Plank GA, et al. Long-term outcome of 
Haemophilus inﬂ uenzae meningitis in Navajo Indian children. 
Arch Pediatr Adolesc Med 1995; 149: 1001–08.
90 Davey PG, Cruikshank JK, McManus IC, Mahood B, Snow MH, 
Geddes AM. Bacterial meningitis—ten years experience. 
J Hyg (Lond) 1982; 88: 383–401.
91 Dawson JA, Wardle R. Detection and prevalence of hearing loss in a 
cohort of children following serogroup B, meningococcal infection 
1983–1987. Public Health 1990; 104: 99–102.
92 Drake R, Dravitski J, Voss L. Hearing in children after 
meningococcal meningitis. J Paediatr Child Health 2000; 36: 240–43.
93 Edwards MS, Baker CJ. Complications and sequelae of 
meningococcal infections in children. J Pediatr 1981; 99: 540–45.
94 Emmett M, Jeﬀ ery H, Chandler D, Dugdale AE. Sequelae of 
Haemophilus inﬂ uenzae meningitis. Aust Paediatr J 1980; 16: 90–93.
95 Erickson L, De Wals P. Complications and sequelae of 
meningococcal disease in Quebec, Canada, 1990–1994. 
Clin Infect Dis 1998; 26: 1159–64.
96 Fakhir S, Ahmad SH, Ahmad P. Prognostic factors inﬂ uencing 
mortality in meningococcal meningitis. Ann Trop Paediatr 1992; 
12: 149–54.
97 Feldman WE, Ginsburg CM, McCracken GH Jr, et al. Relation of 
concentrations of Haemophilus inﬂ uenzae type b in cerebrospinal 
ﬂ uid to late sequelae of patients with meningitis. J Pediatr 1982; 
100: 209–12.
98 Fellick JM, Sills JA, Marzouk O, Hart CA, Cooke RW, Thomson AP. 
Neurodevelopmental outcome in meningococcal disease: a case-
control study. Arch Dis Child 2001; 85: 6–11.
99 Fernandez-Viladrich P, Buenaventura I, Gudiol F, et al. 
Pneumococcal meningitis in adults. A study of 141 episodes. 
Med Clin (Barc) 1986; 87: 569–74 (in Spanish).
100 Ferry PC, Cooper JA, Sitton AB, Sell SHW. Sequelae of Haemophilus 
inﬂ uenzae meningitis: preliminary report of a long-term follow-up 
study. In: Sell SH, Wright PF, eds. Haemophilus inﬂ uenzae. 
Amsterdam: Elsevier, 1982: 111–16.
101 Gilbert GL, Johnson PD, Clements DA. Clinical manifestations and 
outcome of Haemophilus inﬂ uenzae type b disease. 
J Paediatr Child Health 1995; 31: 99–104.
102 Hanna JN, Wild BE. Bacterial meningitis in children under ﬁ ve 
years of age in Western Australia. Med J Aust 1991; 155: 160–64.
103 Honnas A, Petersen LT. Bacterial meningitis in a rural Kenyan 
hospital. East Afr Med J 1998; 75: 396–401.
104 Iatsenko LA, Moiseeva LI. Prognosis of complications in 
generalized forms of meningococcal infection based on various 
nonspeciﬁ c resistance factors. Klin Med (Mosk) 1987; 65: 115–17 
(in Russian).
105 Jakob E, Rubiolo C. Meningococcal meningitis. 
Rev Fac Cien Med Univ Nac Cordoba 1981; 39: 24–39 (in Spanish).
106 Kaplan SL, Catlin FI, Weaver T, Feigin RD. Onset of hearing loss in 
children with bacterial meningitis. Pediatrics 1984; 73: 575–78.
107 Kaplan SL, Goddard J, Van Kleeck M, Catlin FI, Feigin RD. Ataxia 
and deafness in children due to bacterial meningitis. Pediatrics 1981; 
68: 8–13.
108 Kaplan SL, Smith EO, Wills C, Feigin RD. Association between 
preadmission oral antibiotic therapy and cerebrospinal ﬂ uid 
ﬁ ndings and sequelae caused by Haemophilus inﬂ uenzae type b 
meningitis. Pediatr Infect Dis 1986; 5: 626–32.
109 Kastenbauer S, Pﬁ ster HW. Pneumococcal meningitis in adults: 
spectrum of complications and prognostic factors in a series of 
87 cases. Brain 2003; 126: 1015–25.
110 King BA, Richmond P. Pneumococcal meningitis: clinical course 
and resource use in western Australian children. 
J Paediatr Child Health 2004; 40: 606–10.
328 www.thelancet.com/infection   Vol 10   May 2010
Review
111 Kutz JW, Simon LM, Chennupati SK, Giannoni CM, Manolidis S. 
Clinical predictors for hearing loss in children with bacterial 
meningitis. Arch Otolaryngol Head Neck Surg 2006; 132: 941–45.
112 Madhi SA, Madhi A, Petersen K, Khoosal M, Klugman KP. Impact 
of human immunodeﬁ ciency virus type 1 infection on the 
epidemiology and outcome of bacterial meningitis in South African 
children. Int J Infect Dis 2001; 5: 119–25.
113 Mancebo Cortes J, Domingo Pedrol P, Net Castel A, 
Nolla Panades J. Meningococcal meningitis in adults. Study of 
45 cases. Med Clin (Barc) 1984; 83: 655–59 (in Spanish).
114 Mayatepek E, Grauer M, Hansch GM, Sonntag HG. Deafness, 
complement deﬁ ciencies and immunoglobulin status in patients 
with meningococcal diseases due to uncommon serogroups. 
Pediatr Infect Dis J 1993; 12: 808–11.
115 McIntyre P, Jepson R, Leeder S, Irwig L. The outcome of childhood 
Haemophilus inﬂ uenzae meningitis. A population based study. 
Med J Aust 1993; 159: 766–72.
116 Mencia Bartolome S, Casado Flores J, Marin Barba C, 
Gonzalez-Vicent M, Ruiz Lopez MJ. Pneumococcal meningitis in 
children: review of 28 cases. An Esp Pediatr 2000; 53: 94–99 
(in Spanish).
117 Merkelbach S, Sittinger H, Schweizer I, Muller M. Cognitive 
outcome after bacterial meningitis. Acta Neurol Scand 2000; 
102: 118–23.
118 Mertsola J, Kennedy WA, Waagner D, et al. Endotoxin 
concentrations in cerebrospinal ﬂ uid correlate with clinical severity 
and neurologic outcome of Haemophilus inﬂ uenzae type B 
meningitis. Am J Dis Child 1991; 145: 1099–103.
119 Moss PD. Deafness after meningitis. Lancet 1991; 338: 1602.
120 Moyen G, Mbika-Cardorelle A. Bacterial meningitis in infants and 
children at the Brazzaville University Hospital. Arch Pediatr 1999; 
6: 108–09 (in French).
121 Munoz O, Benitez-Diaz L, Martinez MC, Guiscafre H. Hearing loss 
after Hemophilus inﬂ uenzae meningitis. Follow-up study with 
auditory brainstem potentials. Ann Otol Rhinol Laryngol 1983; 
92: 272–75.
122 Muzzio de Califano G, Alarcón N, Rial MJ, Szefner M, Palacio E. 
Meningococcal meningitis: descriptive study of 76 cases in a 
pediatric hospital. Enferm Infecc Microbiol Clin 1997; 15: 451–55 
(in Spanish).
123 Mwangi I, Berkley J, Lowe B, Peshu N, Marsh K, Newton CR. Acute 
bacterial meningitis in children admitted to a rural Kenyan hospital: 
increasing antibiotic resistance and outcome. Pediatr Infect Dis J 
2002; 21: 1042–48.
124 Pﬁ ster HW, Feiden W, Einhaupl KM. Spectrum of complications 
during bacterial meningitis in adults. Results of a prospective 
clinical study. Arch Neurol 1993; 50: 575–81.
125 Pikis A, Kavaliotis J, Tsikoulas J, Andrianopoulos P, Venzon D, 
Manios S. Long-term sequelae of pneumococcal meningitis in 
children. Clin Pediatr (Phila) 1996; 35: 72–78.
126 Rabbani MA, Khan AA, Ali SS, et al. Spectrum of complications 
and mortality of bacterial meningitis: an experience from a 
developing country. J Pak Med Assoc 2003; 53: 580–83.
127 Rasmussen N, Johnsen NJ, Bohr VA. Otologic sequelae after 
pneumococcal meningitis: a survey of 164 consecutive cases with a 
follow-up of 94 survivors. Laryngoscope 1991; 101: 876–82.
128 Rauter L, Mutz I. Haemophilus inﬂ uenzae meningitis 1983 to 
1992—epidemiology and sequelae of the disease. 
Wien Klin Wochenschr 1994; 106: 187–92 (in German).
129 Riordan A, Thomson A, Hodgson J, Hart A. Children who are seen 
but not referred: hearing assessment after bacterial meningitis. 
Br J Audiol 1993; 27: 375–77.
130 Saha SK, Khan NZ, Ahmed AS, et al. Neurodevelopmental sequelae 
in pneumococcal meningitis cases in Bangladesh: a comprehensive 
follow-up study. Clin Infect Dis 2009; 48 (suppl 2): S90–96.
131 Salih MA, Ahmed HS, Osman KA, et al. Clinical features and 
complications of epidemic group A meningococcal disease in 
Sudanese children. Ann Trop Paediatr 1990; 10: 231–38.
132 Sander J, Host JH, Gedde-Dahl TW, et al. Late sequelae after 
meningococcal disease as related to anamnestic and clinical factors 
recorded during the acute illness. NIPH Ann 1984; 7: 69–82.
133 Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J. Patient and 
strain characteristics in relation to the outcome of meningococcal 
disease: a multivariate analysis. Epidemiol Infect 1994; 112: 115–24.
134 Singh K, Mann SB, Gupta AK, Kumar L. Auditory proﬁ le in 
children recovering from bacterial meningitis. Indian J Pediatr 1996; 
63: 210–16.
135 Smith AW, Bradley AK, Wall RA, et al. Sequelae of epidemic 
meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 
1988; 82: 312–20.
136 Spanjaard L, Bol P, de Marie S, Zanen HC. Deafness after 
meningococcal meningitis. Lancet 1992; 339: 560.
137 Streharova A, Krcmery V, Kisac P, et al. Predictors of inferior 
outcome in community acquired bacterial meningitis. 
Neuro Endocrinol Lett 2007; 28 (suppl 3): 2–4.
138 Taylor HG, Michaels RH, Mazur PM, Bauer RE, Liden CB. 
Intellectual, neuropsychological, and achievement outcomes in 
children six to eight years after recovery from Haemophilus 
inﬂ uenzae meningitis. Pediatrics 1984; 74: 198–205.
139 Taylor HG, Mills EL, Ciampi A, et al. The sequelae of Haemophilus 
inﬂ uenzae meningitis in school-age children. N Engl J Med 1990; 
323: 1657–63.
140 Tefuarani N, Vince JD. Purulent meningitis in children: outcome 
using a standard management regimen with chloramphenicol. 
Ann Trop Paediatr 1992; 12: 375–83.
141 Tejani A, Dobias B, Sambursky J. Long-term prognosis after 
H inﬂ uenzae meningitis: prospective evaluation. 
Dev Med Child Neurol 1982; 24: 338–43.
142 Thomas DG. Outcome of paediatric bacterial meningitis 1979–1989. 
Med J Aust 1992; 157: 519–20.
143 Topçu S, Dökmetas I, Yalçin N. Meningococcal meningitis in adults. 
Mikrobiyol Bul 1990; 24: 111–19 (in Turkish).
144 Weststrate W, Hijdra A, de Gans J. Brain infarcts in adults with 
bacterial meningitis. Lancet 1996; 347: 399.
145 Zoons E, Weisfelt M, de Gans J, et al. Seizures in adults with 
bacterial meningitis. Neurology 2008; 70: 2109–15.
146 Ganz ML, Tendulkar SA. Mental health care services for children 
with special health care needs and their family members: 
prevalence and correlates of unmet needs. Pediatrics 2006; 
117: 2138–48.
147 WHO. Global literature review of Haemophilus inﬂ uenzae type b and 
Streptococcus pneumonia invasive disease among children less than 
ﬁ ve years of age: 1980–2005 [WHO/IVB/09.02]. http://whqlibdoc.
who.int/hq/2009/WHO_IVB_09.02_eng.pdf 
(accessed Mar 17, 2010).
148 Smith PS, Morrow RH. Field trials of health interventions in 
developing countries: a toolbox (2nd edn). Oxford: Macmillan 
Education, 1996. 
149 Hennekens CH, Buring JE. Epidemiology in medicine (1st edn). 
Boston/Toronto: Little, Brown and Company, 1987.
150 Feigin RD, Stechenberg BW, Chang MJ, et al. Prospective 
evaluation of treatment of Hemophilus inﬂ uenzae meningitis. 
J Pediatr 1976; 88: 542–48.
151 Anderson V, Anderson P, Grimwood K, Nolan T. Cognitive and 
executive function 12 years after childhood bacterial meningitis: 
eﬀ ect of acute neurologic complications and age of onset. 
J Pediatr Psychol 2004; 29: 67–81.
152 Holt DE, Halket S, de Louvois J, Harvey D. Neonatal meningitis in 
England and Wales: 10 years on. Arch Dis Child Fetal Neonatal Ed 
2001; 84: F85–89.
153 Kilpi T, Anttila M, Kallio MJ, Peltola H. Severity of childhood 
bacterial meningitis and duration of illness before diagnosis. Lancet 
1991; 338: 406–09.
154 Victora CG, Wagstaﬀ  A, Schellenberg JA, Gwatkin D, Claeson M, 
Habicht JP. Applying an equity lens to child health and mortality: 
more of the same is not enough. Lancet 2003; 362: 233–41.
155 Duke T, Tamburlini G, Silimperi D. Improving the quality of 
paediatric care in peripheral hospitals in developing countries. 
Arch Dis Child 2003; 88: 563–65.
156 Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R, 
Pinel J. Substandard medicines in resource-poor settings: a 
problem that can no longer be ignored. Trop Med Int Health 2008; 
13: 1062–72.
157 Angus DC, Black N. Improving care of the critically ill: institutional 
and health-care system approaches. Lancet 2004; 363: 1314–20.
